All News

obesity.knee_.arthritis.jpg

Triple Hormone Receptor Agonist for Treatment of Obesity and Knee Osteoarthritis

Jack Cush, MD

The NEJJM reports that Retatrutide, an investigational incretin agent, was shown to

Read Article
RheumNow Podcast square

Remission – Believe it or Not (10.2.2026)

Jack Cush, MD

Dr, Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article
obesity,scale,weight

Link Between Obesity and Psoriatic Arthritis

Jack Cush, MD

Obesity is an incidental comorbidity in psoriatic arthritis (PsA). It is a modifiable, mechanistically active driver of disease onset, severity, and treatment failure. A new comprehensive review in RMD Open (Madsen et al., 2026) synthesizes 49 studies suggesting that weight management belongs in the core PsA treatment algorithm.

Read Article
question mark

The weight is off, the DMARDs are off - now what?

David Liew, FRACP

That promised land of substantive weight loss comes within it the illusion of better disease control and, for inflammatory arthritis patients, the possibility of reducing the burden of regular medicines - often driven by the patient, with or without telling you. It is a dream worth aspiring to and, as we’ve discussed this month, one which is increasingly achievable, albeit still for a small minority of patients. So for those who do reach that ultimate goal, what next?

Read Article
diet,greek,mediterranean,salad

Mediterranean Diet Lowers Incident Rheumatoid Arthritis Risk

Jack Cush, MD

The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of incident rheumatoid arthritis (RA), but not psoriasis. 

Read Article
woman,doctor

Bringing TOGETHER-PsA Into Clinical Practice

Eric Dein, MD

When Ms. RS came into my clinic for a new patient evaluation, she was suffering from highly active skin disease, joint swelling, pain and poor mobility. Her body mass index was 46, indicating class III obesity. A treatment plan focused solely on her inflammatory disease without addressing her weight would not fully address her overall disease burden.

Read Article
BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001).  1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/Ko7VI3ZAC0

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/ZbVwGTy0rG
Dr. John Cush RheumNow ( View Tweet)
The GLP-1 Opportunity Cost in Rheumatology There is no doubt it is an incredibly exciting time to be tackling obesity-related diseases, like many rheumatic diseases appear to be, to some extent. https://t.co/49EscdPOTG https://t.co/c0kSgOXZy7

Links:

Dr. John Cush RheumNow ( View Tweet)
The weight is off, the DMARDs are off - now what? Sometimes it’s only when we have effective solutions that we have to think about what to do next. And when that happens, remember why we do things in the first place. In an era when weight loss is happening on scale, now we need https://t.co/MTjU5YRS5q
Dr. John Cush RheumNow ( View Tweet)
Treatment for Obesity and Inflammation, but at what Cost? https://t.co/v87FxQqrAv https://t.co/Oonrexyp0F

Links:

Dr. John Cush RheumNow ( View Tweet)
Obesity & Biologic Treatment Response Prepared for "The Obesity Imperative" campaign. https://t.co/72TFW6BWgG https://t.co/XWFWoH2D33

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Managing Muscle and Fat Loss with GLP-1s Dr. David Liew, Melbourne, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign presented in September 2026. https://t.co/t9uD7TGKjZ https://t.co/BzE1m04E2s

Links:

Dr. John Cush RheumNow ( View Tweet)
Mediterranean Diet Lowers Incident Rheumatoid Arthritis Risk The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of https://t.co/9GhEwXuCEI
Dr. John Cush RheumNow ( View Tweet)
Bringing TOGETHER-PsA Into Clinical Practice The TOGETHER-PsA trial provides prospective evidence supporting an integrated approach to PsA and weight management, reinforcing the importance of addressing both inflammatory disease activity and metabolic health as part of https://t.co/WmF4mdxDWR
Dr. John Cush RheumNow ( View Tweet)
The Need for Weight Loss and Weight Gain in the ILD Clinic https://t.co/UaKW9GPJTN https://t.co/QGYblSxbfP

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/qSXZkyYTmZ
Dr. John Cush RheumNow ( View Tweet)
Lifestyle and Incretin Therapy Advice for Rheumatologists As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to https://t.co/9dfmKLuJF7
Dr. John Cush RheumNow ( View Tweet)
BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001).  1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/BoSgFoOyNN

Links:

Dr. John Cush RheumNow ( View Tweet)
Obesity and Psoriatic Disease Obesity is a clinically important comorbidity in psoriasis (PsO) and psoriatic arthritis (PsA). Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic https://t.co/WVIqfq8vEj
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×